K V Pharmaceutical Co. Class A (NYSE:KV-A)
CAPS Rating:
Develops advanced drug delivery technologies which enhance the effectiveness of new therapeutic agents, existing pharmaceutical products and prescription nutritional products.
RSS Headlines
Fool UK
Recs
Too much uncertainty right now, still coming under heavy fire, significant price drop on Makena will hurt margins going forward, stock still up quite a bit since FDA approval (even with recent plunge). Too risky for my blood.